CommercialCoverageHigh impact
[New York] Updates to Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines
Anthem BCBS·NY · Vascular Surgery, Cardiology, Oncology +2 more·Provider Bulletin
Effective date
Nov 15, 2026
We identified it
Aug 12, 2026
Summary
Carelon Medical Benefits Management has updated clinical appropriateness guidelines effective November 15, 2026, with significant changes to vascular procedures, genetic/molecular testing criteria, and cancer treatment indications. Key changes include expanded indications for varicose vein treatments, new drug eligibility for cancer molecular testing (imlunestrant, niraparib, talazoparib), broader genetic testing requirements across multiple cancer types, and removal of certain age/stage restrictions. Billing teams must review each clinical area for prior authorization and medical necessity documentation changes.
Action Required
By November 15, 2026: Billing team and clinical staff must implement the following changes in Anthem/Carelon authorization system and documentation templates: (1) Vascular procedures - Update prior auth criteria for inframalleolar angioplasty (critical limb ischemia), thermal/non-thermal ablation of varicose veins, cyanoacrylate ablation for perforators, and genicular artery embolization (now requires case-by-case review, not automatically approved); (2) Genetic/Molecular Testing - Modify authorization rules to require all test components demonstrate clinical utility; add imlunestrant, niraparib, and talazoparib as eligible triggers for ESR1/BRCA/HRD testing; expand breast cancer molecular testing to stages IIB, IIIA, IIIB, IIIC (previously metastatic only); remove stage restrictions for pancreatic cancer testing; broaden prostate cancer testing to all metastatic indications (not just mCSPC); (3) PFO Closure - Establish age cutoff at 60 years (not medically necessary if older); require RoPE score documentation; (4) Vascular Embolization - Update indications for liver malignancy (add DEB-TACE, add drug-eluting bead criteria), portal vein embolization (now includes primary tumors), varicocele treatment, and complex congenital heart disease collaterals; (5) Cancer Genetic Testing - Deny ctHPV DNA for oropharyngeal carcinoma recurrence; expand tissue-agnostic testing to include HER2; update comprehensive molecular panels for biliary, bladder, thyroid, and unknown primary cancers. Providers must update clinical documentation templates to capture new eligibility criteria. Deny claims for: WES/WGS/WTA testing; genicular artery embolization without medical justification; PFO closure in patients >60 years; breast cancer recurrence molecular testing; NIFTP somatic testing; isolated labial/lower extremity varicose veins without pelvic symptoms. Update denial templates and appeal guidelines before effective date to avoid processing delays.